Methylone (3, 4-Methylenedioxy-N-methylcathinone), a β-keto analog of 3,4-methylenedioxy-N-methylamphetamine (MDMA) is a stimulant and psychoactive drug. Methylone is a popular drug of abuse that strongly increases the release of the three monoamines: dopamine, serotonin (5-HT) and norepinephrine. In addition, methylone inhibits plasma membrane catecholamine transporters but only weakly inhibit the vesicle transporter. In April 2013, methylone was listed in the Schedule 1 substance under the Controlled Substances Act.

EAM-2201 acts as a full agonist with of cannabinoid receptors, CB1 and CB2. This compound was first identified in Japan in 2012 as an ingredient in synthetic cannabis smoking blends and belongs to narcotic substances, that is why was banned in some countries.